An elevated TMB correlated with increased response to immuno-oncological drugs in multiple clinical trials, of which five evaluated the efficacy of a combination of anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) and neoadjuvant chemotherapy in TNBC cancer patients. The gene discussed is CD274; the disease is cancer.